hotspot -WSS

hotspot

author：knowledge 2025-10-01 17:18:53 - browse：66553

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Readers respond to H5N1 and livestock movements, and more

hotspot

focus

WSS

Woman found dead after suspected bear encounter near Yellowstone, wildlife officials say

Malaysia cuts short music fest after British band slams anti

Burning questions about Delta and the next phase of the Covid pandemic

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Malaysia cuts short music fest after British band slams anti

FAMU bans football players from facility after release of rap video shot in team's locker room

explore

hotspot

explore

Novavax promises a turnaround & Lilly roils the obesity market

NVIDIA and Google execs on the future of AI and drug discovery

Trump demands the U.S. pay no more for drugs than other countries … again

Mike Pence ‘not interested in trading insults’ with Trump as he tries to win New Hampshire

Cancer drug shortages should be causing more outrage

Wearables generate powerful data but its not useful to doctors, yet

Psychedelics group wrestles with new pharma identity

Mike Pence ‘not interested in trading insults’ with Trump as he tries to win New Hampshire

Psychedelics group wrestles with new pharma identity

Cytokinetics CEO stresses company can launch heart drug on its own

leisure time

Readers respond to H5N1 and livestock movements, and more

Criminal prosecution for violating HIPAA: an emerging threat

It's time to retire 'poor historian' from clinicians' vocabularies

Mike Pence ‘not interested in trading insults’ with Trump as he tries to win New Hampshire

Criminal prosecution for violating HIPAA: an emerging threat

Men with early prostate cancer can safely opt out of treatment

focus

hotspot

focus

Wikipedia